Boltz and Takeda partner on biomolecular AI to speed drug R&D

On June 19, 2026, Boltz PBC announced a collaboration with Takeda to deploy its biomolecular AI models and platform across Takeda’s research organization. The deal gives Takeda scientists access to foundation models such as BoltzMol-1 and BoltzProt-1 via the Boltz Lab interface and API to support structure prediction, affinity estimation and generative molecular design.